Related Experiment Video
Updated: Feb 2, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma
Xianzhou Song1, Hui Chen1, Chengwei Zhang1
1Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, 77030, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant and lethal disease with few treatment options. Steroid receptor coactivator-3 (SRC-3, also known as NCOA3, AIB1, pCIP, ACTR, RAC3, TRAM1) sits at the nexus of many growth signaling pathways and has been pursued as a therapeutic target for breast, prostate and lung cancers. In this study, we find that SRC-3 is overexpressed in PDAC and inversely correlates with patient overall survival. Knockdown of SRC-3 reduces pancreatic cancer cell proliferation, migration and invasion in vitro. Additionally, inhibition of SRC-3 using either shRNA or a small molecule inhibitor can significantly inhibit tumor growth in orthotopic pancreatic cancer mouse models. Collectively, this study establishes SRC-3 as a promising therapeutic target for pancreatic cancer treatment.
Insights
Steroid receptor coactivator-3 (SRC-3) is overexpressed in pancreatic cancer, driving tumor growth and invasion. Inhibiting SRC-3 offers a promising new therapeutic strategy for this lethal disease.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited therapeutic options.
- Steroid receptor coactivator-3 (SRC-3) is implicated in various cancer growth pathways and is a potential therapeutic target.
Purpose of the Study:
- To investigate the role of SRC-3 in PDAC.
- To evaluate SRC-3 as a potential therapeutic target for pancreatic cancer.
Main Methods:
- Analysis of SRC-3 expression in PDAC tissues and correlation with patient survival.
- In vitro studies involving SRC-3 knockdown in pancreatic cancer cell lines to assess proliferation, migration, and invasion.
- In vivo studies using orthotopic pancreatic cancer mouse models to evaluate tumor growth inhibition via SRC-3 inhibition (shRNA and small molecule inhibitor).
Main Results:
- SRC-3 is overexpressed in PDAC and correlates inversely with patient survival.
- Knockdown of SRC-3 significantly reduced pancreatic cancer cell proliferation, migration, and invasion in vitro.
- Inhibition of SRC-3 led to significant inhibition of tumor growth in orthotopic pancreatic cancer mouse models.
Conclusions:
- SRC-3 plays a critical role in PDAC progression.
- Targeting SRC-3 represents a promising therapeutic strategy for pancreatic cancer treatment.
More Related Videos
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Block Diagram Reduction
The first step in this process is the identification and relocation of a branch point. A branch point, where a...
Elements of Block Diagrams
A block diagram typically includes essential elements such as comparators, blocks, and feedback loops. Each of these elements...
Population Growth
Primary and Secondary Growth in Roots and Shoots